Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 11/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23126467 | 1.00 | RET (0.38) | RETMAPKAPK2CNR1CNR2RAF1 | |
| SCHEMBL30809736 | 1.00 | RET (0.38) | RETMAPKAPK2CNR1CNR2RAF1 | |
| SCHEMBL23064027 | 0.91 | CNR1 (0.31) | RETCNR1CNR2KIF18A | |
| SCHEMBL23126464 | 0.86 | RET (0.41) | RETMAPKAPK2CNR1CNR2DRD2 | |
| SCHEMBL30809737 | 0.84 | RET (0.34) | RETCNR1CNR2RAF1DRD2 | |
| SCHEMBL23126465 | 0.82 | RET (0.38) | RETCNR1CNR2JAK3BTK | |
| SCHEMBL30809728 | 0.82 | RET (0.38) | RETCNR1CNR2JAK3BTK | |
| SCHEMBL28520538 | 0.81 | PTPN11 (0.32) | CNR2KIF18A | |
| SCHEMBL23063934 | 0.79 | RET (0.39) | RETMAPKAPK2CNR1CNR2RAF1 | |
| SCHEMBL23126466 | 0.78 | RET (0.33) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | RET 121/4885MAPKAPK2 149/4885CNR1 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.